论文部分内容阅读
“降价不是药品招标的唯一目的,政府正在构建沟通药 品生产企业、医疗机构和政府三者之间的信息渠道,以减轻 药品生产企业的招投标负担。”卫生部规划财务司的王玉洵 处长说,此举旨在保证药品招标的继续推行,既能让老百姓 用上质量良好、价格合理的药品,又能降低医药企业参与招 标的成本。 在日前召开的“2002年中国上海国际生物技术和医药 研讨会”上,当被间及近来不少药品生产企业对于药品降价 叫苦不迭,京、沪等地甚至出现一些价格低廉的经典药品无 人生产、大夫无药可用的尴尬局面时,王玉洵承认,由于目前 药品价格形成机制和医疗机构补偿机制尚不健全、药品生产 能力供大于求、药品流通秩序混乱等诸多因素的相互作用, 药品购销中的不正之风得以滋生蔓延。方方面面,尤其是药 品生产企业,参与药品集中采购投标的成本的确很高,付出
“The price reduction is not the sole purpose of drug bidding. The government is building channels of communication between drug manufacturers, medical institutions and the government to ease the bidding burden on drug manufacturers.” Director Wang Yuhuan of the Planning and Finance Department of the Ministry of Health said , The move aims to ensure the continued implementation of drug bidding, both to allow people to use good quality, reasonably priced drugs, but also reduce the cost of pharmaceutical companies to participate in the bidding. In the recently held “Shanghai International Biotechnology and Pharmaceutical Symposium 2002”, when many pharmaceutical manufacturers were recently complaining about price cuts of drugs, there were even some low-priced classical medicines in Beijing, Shanghai and other places Wang Yukuo admits that due to the current drug price formation mechanism and the medical institutions compensation mechanism is not perfect, oversupply of drug production capacity, chaotic circulation of drugs and many other factors in the interaction between drug purchase and sale The unhealthy trend to breed. In all respects, especially the pharmaceutical manufacturing enterprises, the cost of participating in centralized bidding for medicines is indeed very high.